Therapeutic management of hyperlipoproteinemia (a)

Drugs in Context

article

Constantine E Kosmas¹  Andreas Sourlas²  Gordon Mallarkey³  Delia Silverio⁴  Domingo Y Ynoa⁴  Peter D Montan⁴  Eliscer Guzman¹  Mario J Garcia¹ 

[1]Department of Medicine, Division of Cardiology, Montefiore Medical Center

[2]School of Medicine, University of Crete

[3]BioExcel Publishing Ltd

[4]Cardiology Clinic, Cardiology Unlimited PC

关键词: cardiovascular disease;    cardiovascular risk;    hyperlipoproteinemia (a);    lipoprotein (a);    therapeutic management;   

DOI  :  10.7573/dic.212609

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

Cardiovascular disease (CVD) has consistently been the leadingcause of death worldwide. Several clinical and epidemiologicalstudies have demonstrated that an elevated plasma concentrationof lipoprotein (a) [Lp(a)] is a causative and independent majorrisk factor for the development of CVD, as well as calcificaortic valve stenosis. Thus, the therapeutic managementof hyperlipoproteinemia (a) has received much attention, assignificant reductions in Lp(a) levels may, potentially, favorablyaffect cardiovascular risk. Aspirin, niacin, estrogens, and statins,which act on different molecular pathways, may be prescribedto patients with mild or modest elevations of Lp(a) levels.Other therapeutic interventions, such as proprotein convertasesubtilisin/kexin type 9 (PCSK9) inhibitors, Lp(a) apheresis, andthe novel antisense oligonucleotides APO(a)-Rx and APO(a)-LRx,which are being evaluated in ongoing clinical trials, have providedsome promising results and can potentially be used in severe casesof hyperlipoproteinemia (a). This review aims to present and discussthe current clinical and scientific data pertaining to the therapeuticoptions for the management of hyperlipoproteinemia (a).

【 授权许可】

CC BY-NC-ND